Cargando…
Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
Previous report showed that a variety of icotinib derivatives bearing different 1,2,3-triazole moieties, which could be readily prepared via copper (I)-catalyzed cycloaddition (CuAAC) reaction between icotinib and different azides, exhibited interesting activity against different lung cancer cell li...
Autores principales: | Chen, Xiaojie, Mao, Long-Fei, Tian, Siqi, Tian, Xueli, Meng, Xueqiong, Wang, Mu-Kuo, Xu, Weifeng, Li, Yue-Ming, Liu, Kangdong, Dong, Zigang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709406/ https://www.ncbi.nlm.nih.gov/pubmed/36467103 http://dx.doi.org/10.3389/fphar.2022.1028692 |
Ejemplares similares
-
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020) -
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo
por: Jia, Xuechao, et al.
Publicado: (2021) -
Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma
por: Li, Zhenzhen, et al.
Publicado: (2020) -
FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
por: Zhu, Zuoquan, et al.
Publicado: (2021) -
3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo
por: Ma, Fayang, et al.
Publicado: (2022)